XML 32 R13.htm IDEA: XBRL DOCUMENT

Common Stock Warrants and Options

3 Months Ended

Mar. 31, 2025

Common Stock Warrants And Options

Common Stock Warrants and Options

Note 6 – Common Stock Warrants and Options

Common Stock Warrants

Stock warrant transactions for the three months ended March 31, 2025 were as follows:

Schedule of Warrant Activity

	Three Months Ended March 31, 2025
	Number of			Weighted Average
	Warrants			Exercise Price
Warrants outstanding at December 31, 2024		1,120,429		$	18.85
Granted		951,534			2.05
Forfeited/cancelled		—			—
Exercised		(302,069	)		1.35
Warrants outstanding at March 31, 2025		1,769,894		$	11.91
Warrants exercisable at March 31, 2025		1,769,894		$	11.91

As of March 31, 2025, all outstanding warrants were fully vested and exercisable and had an aggregate intrinsic value of approximately $780,000 based on the fair value of the Company’s common stock on March 31, 2025.

Warrants outstanding as of March 31, 2025 are exercisable as follows:

		Warrants Outstanding and Exercisable as of March 31, 2025
Range of Exercise Price		Number Outstanding		Weighted Average Remaining Contractual Life (Years)		Weighted Average Exercise Price
$	0.0001		326,251		N/A	$	0.0001
	2.02		604,138		3.2		2.02
	2.8375		21,145		4.9		2.8375
	4.35		437,931		4.2		4.35
	5.4375		88,800		4.2		5.4375
	30.00		216,666		3.3		30.00
	37.50		13,000		2.8		37.50
	102.00		1,867		0.3		102.00
	165.00		52,316		0.9		165.00
	206.25		7,780		0.9		206.25
			1,769,894		3.5		11.91

Common Stock Options

In April 2022 the Company established the 2022 Omnibus Incentive Plan (the “Plan”). The Plan was approved by our Board and stockholders. The purpose of the Plan is to grant stock and options to purchase our common stock, and other incentive awards, to our employees, directors, and key consultants. The maximum number of shares of common stock that may be issued pursuant to awards granted under the Plan is 166,667. The shares of our common stock underlying cancelled and forfeited awards issued under the Plan may again become available for grant under the Plan. As of March 31, 2025, there were 124,600 stock options outstanding and 25,935 shares of restricted stock granted in prior years under the Plan, which left 16,132 shares available for grant under the Plan. The following table summarizes stock option transactions for the three months ended March 31, 2025:

Schedule of Options Activity

	Three Months Ended March 31, 2025
	Number of		Weighted Average
	Options		Exercise Price
Options outstanding at December 31, 2024		124,600	$	32.69
Granted		—		—
Forfeited/cancelled		—		—
Exercised		—		—
Options outstanding at March 31, 2025		124,600	$	32.69
Options exercisable at March 31, 2025		107,746	$	37.47

The weighted average remaining contractual life of all options outstanding, and all options vested and exercisable as of March 31, 2025 was 8.0 years. Furthermore, the aggregate intrinsic value of all options outstanding and all options vested and exercisable as of March 31, 2025 was approximately $1,000 and $0, respectively, in each case based on the fair value of the Company’s common stock on March 31, 2025.

The total fair value of options that vested during the three months ended March 31, 2025 and 2024, was $3,000 and $102,000, respectively, and is included in selling, general and administrative expense in the accompanying unaudited condensed statements of operations. As of March 31, 2025, 107,746 stock options were vested and exercisable and unvested compensation expense amounted to approximately $29,000.

Options outstanding as of March 31, 2025 are exercisable as follows:

		Stock Options Exercisable as of March 31, 2025
Range of Exercise Price		Number Outstanding		Weighted Average Remaining Contractual Life (Years)		Weighted Average Exercise Price
$	2.11		6,482		9.6	$	2.11
	10.50		16,666		8.0		10.50
	25.50		50,000		7.8		25.50
	74.40		34,598		7.3		74.40
			107,746